O uso do clopidogrel no tratamento do infarto agudo do miocárdio com supradesnivelamento de ST
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Avaliar a eficácia do clopidogrel frente aos demais antiplaquetários, demonstrando seu uso em distintas populações e sua associação com a mortalidade. Métodos: Foram realizadas buscas nas bases de dados PubMed e Biblioteca Virtual em Saúde (BVS) e incluídos os estudos publicados entre 2018-2023, ensaio clínico controlado, estudo observacional, textos completos e gratuitos e excluídos artigos fora do tema e duplicados. Resultados: Foram incluídos 25 artigos para a síntese narrativa, onde através da análise dos estudos, observou-se que o clopidogrel, apesar de não ser o antiplaquetário mais recomendado atualmente, é o mais utilizado devido aos custos financeiros e pela sua confiabilidade no uso, e que fatores como idade superior a 75 anos, interações medicamentosas e o uso crônico do mesmo apresenta desfechos favoráveis. Considerações finais: Pode se considerar que o uso do clopidogrel no infarto agudo do miocárdio com supradesnivelamento do seguimento st apresenta certa desvantagem quando comparado aos outros antiplaquetários, no entanto, o seu uso é descrito de forma confiável e considerado um bom inibidor do receptor P2Y12. Os presentes estudos não foram capazes de comprovar de forma segura a sua superioridade ou inferioridade diante dos outros medicamentos, visto que a população, cultura e países foram distintas.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ABTAN J, et al. Periprocedural outcomes according to timing of clopidogrel loading dose in patients who did not receive P2Y12 inhibitor pretreatment. Circ Cardiovasc Interv. 2019; 12(3): e007811.
3. AKITA K, et al. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62,737 patients with acute coronary syndromes: a nationwide registry study in Japan. Eur Heart J Cardiovasc Pharmacother., 2019.
4. ALMENDRO-DELIA M, et al. Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: an on-treatment analysis from a multicenter registry. Front Cardiovasc Med., 2022; 9.
5. BERWANGER O, et al. Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: practical perspectives based on data from the TREAT study. Clin Cardiol., 2018; 41(10): 1322-1327.
6. CALDEIRA D, et al. Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: contemporaneous Portuguese cross-sectional data. Rev Port Cardiol., 2019; 38(11): 809-814.
7. DE LUCA L, et al. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. Eur Heart J Cardiovasc Pharmacother., 2021; 7(2): 94-103.
8. ESTEVE-PASTOR MA, et al. Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes. J Cardiovasc Pharmacol Ther., 2018; 23(1): 57-65.
9. FARIDI K, et al. Physician and hospital utilization of P2Y12 inhibitors in ST-segment–elevation myocardial infarction in the United States. Circ Cardiovasc Qual Outcomes, 2020; 13(3).
10. GAGER GM, et al. Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients. Eur J Clin Investig., 2020; 50(11).
11. Hautamäki M, et al. Prehospital adenosine diphosphate receptor blocker use, culprit artery flow, and mortality in STEMI: the MADDEC study. Clin Drug Investig., 2021.
12. HULOT JS, et al. Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI. JACC Cardiovasc Interv., 2020; 13(5): 621-630.
13. LAGHLAM D, et al. Évolution démographique, caractéristiques et suivi clinique intrahospitalier des sujets âgés traités par angioplastie primaire pour syndrome coronarien aigu avec sus-décalage du segment ST. Ann Cardiol Angeiol., 2019; 68(1): 6-12.
14. LI XY, et al. Switching from ticagrelor to clopidogrel in patients with ST‐segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real‐world China: occurrences, reasons, and long‐term clinical outcomes. Clin Cardiol., 2018; 41(11): 1446-1454.
15. LIN TT, et al. Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. BMC Geriatr., 2018; 18.
16. PARK DW, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management. Circulation, 2019; 140(23): 1865-1877.
17. PEREIRA NETO AH, POLANCZYK C. Tempos de atendimento e desfechos no infarto agudo do miocárdio com supradesnivelamento ST. Rev Soc Bras Clin Med., 2021;20-28.
18. PRAMI T, et al. Concomitant use of drugs known to cause interactions with oral antiplatelets—polypharmacy in acute coronary syndrome outpatients in Finland. Eur J Clin Pharmacol., 2019; 76(2): 257-265.
19. PUFULETE M, et al. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a “target trial”. Open Heart, 2022; 9(2): e001999.
20. REGEV E, et al. Acute myocardial infarction occurring while on chronic clopidogrel therapy (“clopidogrel failure”) is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. PLoS One, 2018; 13(4): e0195504.
21. SAWHNEY JPS, et al. Short- and long-term follow-up of antithrombotic management patterns in patients hospitalized with acute coronary syndrome: Indian subgroup of EPICOR Asia study. Indian Heart J., 2015; 71(1): 25-31.
22. SCANAVINI-FILHO MA, et al. Effects of ticagrelor and clopidogrel on coronary microcirculation in patients with acute myocardial infarction. Adv Ther., 2022; 39(4): 1832-1843.
23. SINNAEVE P, et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol., 2020; 75(20): 2588-2597.
24. SUKMAWAN R, et al. Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Pharmacol Res Perspect., 2021; 9(2).
25. VÖLZ S, et al. Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish Coronary Angiography and Angioplasty Registry. J Am Heart Assoc., 2020; 9(14).
26. YAN XQ, et al. Platelet-fibrin clot strength measured by thromboelastography could predict hypercoagulability and antiplatelet effects in patients after percutaneous coronary intervention. Ann Palliat Med., 2021; 10(3): 2448457-2442457.